Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cadonilimab + TACE
- Development stage
- Phase 2
- Lead developer
- Akeso
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous, Intra-arterial
01
Overview
Cadonilimab + TACE is a combination therapy that pairs a bispecific antibody targeting PD-1 and CTLA-4 immune checkpoints (cadonilimab) with Transarterial Chemoembolization (TACE), a minimally invasive procedure that delivers chemotherapy directly to liver tumors while blocking their blood supply. This approach combines immunotherapy with localized chemotherapy and embolization to treat hepatocellular carcinoma.
02
Targets
CTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on cadonilimab + TACE.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cadonilimab + TACE.